What is driving IDIA.SW stock today?

IDIA.SW stock is moving on a mix of clinical news and commercial approvals. A Phase 2 psoriasis trial start and Health Canada approval for JERAYGO are the main drivers, combined with above‑average intraday volume of 3,509,266.

What is Meyka AI's view on IDIA.SW stock?

Meyka AI rates IDIA.SW **73.07/100** (Grade B+, Suggestion BUY) and models a quarterly price of **CHF5.81**, implying roughly **43.00%** upside versus **CHF4.06**. This is a model projection, not investment advice.

Which catalysts should traders watch for IDIA.SW stock?

Watch the Phase 2 psoriasis readout expected in Q1 2027 and the next earnings on 26 Feb 2026. Regulatory updates for JERAYGO commercialization will also influence short‑term trading.

Is IDIA.SW stock overvalued versus peers?

Valuation metrics show price‑to‑sales **3.65** and EV/Revenue **8.82**, above many large healthcare peers. That reflects pipeline optionality but increases sensitivity to trial outcomes and revenue execution.

CH Stocks

IDIA.SW down 4.58% to CHF4.06 on 06 Jan 2026: volume surge hints momentum

ByDanny Kontos January 6, 2026January 6, 2026

IDIA.SW stock trades at CHF4.06, down 4.58% intraday on 06 Jan 2026, with volume at 3,509,266 on the SIX exchange in Switzerland. The move follows a mix of clinical progress and a recent Canadian approval update that keep Idorsia in active trade lists today. Investors are watching liquidity and technical signals after the stock opened at CHF4.44 and hit a day high of CHF4.65. We summarise the drivers, financials, technicals, Meyka AI grade and what the intraday volume spike may mean for short-term momentum.